Please provide your email address to receive an email when new articles are posted on . The use of vascular endothelial growth factor receptor tyrosine kinase inhibitors significantly increased the ...

Treatment with oral VEGFR-TKIs may carry an increased risk of aneurysm and artery dissection. Tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFR-TKIs) are ...

A 65-year-old man presented with episodes of fainting. Assessment showed his symptoms were related to compression of the superior vena cava from extensive swelling of the supraclavicular, mediastinal, ...

Preoperative VEGFR-TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment ...

Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). Background: Several small molecule tyrosine kinase inhibitors (TKI) targeting ...

Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth.

Treatment with a vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFR–TKI) after previous treatment with checkpoint-inhibitor therapy alone or in combination with a VEGFR–TKI ...

Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. A phase I/II study of photodynamic therapy (PDT) using HPPH for the treatment of Barrett's ...

Beyang Therapeutics Co. Ltd. has divulged salts of vascular endothelial growth factor receptor (VEGFR) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory, ...

“The present study analyzed PDGFR and VEGFR expression in primary colon cancer tissues and CRC cell lines in order to better define their expression profiles. Furthermore, we analyzed putative PDGF ...

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the ...